Literature DB >> 32534953

CYP2J2 Molecular Recognition: A New Axis for Therapeutic Design.

Aditi Das1, Austin T Weigle2, William R Arnold3, Justin S Kim4, Lauren N Carnevale3, Hannah C Huff2.   

Abstract

Cytochrome P450 (CYP) epoxygenases are a special subset of heme-containing CYP enzymes capable of performing the epoxidation of polyunsaturated fatty acids (PUFA) and the metabolism of xenobiotics. This dual functionality positions epoxygenases along a metabolic crossroad. Therefore, structure-function studies are critical for understanding their role in bioactive oxy-lipid synthesis, drug-PUFA interactions, and for designing therapeutics that directly target the epoxygenases. To better exploit CYP epoxygenases as therapeutic targets, there is a need for improved understanding of epoxygenase structure-function. Of the characterized epoxygenases, human CYP2J2 stands out as a potential target because of its role in cardiovascular physiology. In this review, the early research on the discovery and activity of epoxygenases is contextualized to more recent advances in CYP epoxygenase enzymology with respect to PUFA and drug metabolism. Additionally, this review employs CYP2J2 epoxygenase as a model system to highlight both the seminal works and recent advances in epoxygenase enzymology. Herein we cover CYP2J2's interactions with PUFAs and xenobiotics, its tissue-specific physiological roles in diseased states, and its structural features that enable epoxygenase function. Additionally, the enumeration of research on CYP2J2 identifies the future needs for the molecular characterization of CYP2J2 to enable a new axis of therapeutic design.
Copyright © 2020. Published by Elsevier Inc.

Entities:  

Keywords:  Bioactive lipid mediators; Cytochrome P450 enzymes; Drug-drug interactions; Epoxygenase; Polyunsaturated fatty acids; Structure-function

Year:  2020        PMID: 32534953     DOI: 10.1016/j.pharmthera.2020.107601

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  8 in total

1.  Anthracycline derivatives inhibit cardiac CYP2J2.

Authors:  Justin S Kim; Andres S Arango; Swapnil Shah; William R Arnold; Emad Tajkhorshid; Aditi Das
Journal:  J Inorg Biochem       Date:  2022-01-13       Impact factor: 4.155

Review 2.  Nanodiscs: A toolkit for membrane protein science.

Authors:  Stephen G Sligar; Ilia G Denisov
Journal:  Protein Sci       Date:  2020-11-16       Impact factor: 6.993

3.  Molecular determinant of substrate binding and specificity of cytochrome P450 2J2.

Authors:  Liang Xu; Liao Y Chen
Journal:  Sci Rep       Date:  2020-12-17       Impact factor: 4.379

Review 4.  The Role of Epoxyeicosatrienoic Acids in Cardiac Remodeling.

Authors:  Jinsheng Lai; Chen Chen
Journal:  Front Physiol       Date:  2021-02-24       Impact factor: 4.566

5.  Acetylshikonin, A Novel CYP2J2 Inhibitor, Induces Apoptosis in RCC Cells via FOXO3 Activation and ROS Elevation.

Authors:  Heui Min Lim; Jongsung Lee; Seon Hak Yu; Myeong Jin Nam; Hyo Sun Cha; Kyungmoon Park; Yung-Hun Yang; Kyu Yun Jang; See-Hyoung Park
Journal:  Oxid Med Cell Longev       Date:  2022-03-09       Impact factor: 6.543

6.  Artemether inhibits proliferation, invasion and migration of hepatocellular carcinoma cells via targeting of CYP2J2.

Authors:  Xionglin Zhu; Mei Yang; Zhiling Song; Guangbing Yao; Qifeng Shi
Journal:  Oncol Lett       Date:  2022-04-14       Impact factor: 3.111

7.  Evaluation of Herb-Drug Interaction Between Danshen and Rivaroxaban in Rat and Human Liver Microsomes.

Authors:  Xu Wang; Jingjing Fa; Yuanjin Zhang; Shengbo Huang; Jie Liu; Junqing Gao; Lina Xing; Zongjun Liu; Xin Wang
Journal:  Front Pharmacol       Date:  2022-07-19       Impact factor: 5.988

Review 8.  Drug-drug-gene interactions as mediators of adverse drug reactions to diclofenac and statins: a case report and literature review.

Authors:  Nada Božina; Lana Ganoci; Livija Simičević; Katarina Gvozdanović; Iva Klarica Domjanović; Margareta Fistrek Prlić; Tena Križ; Ana Borić Bilušić; Mario Laganović; Tamara Božina
Journal:  Arh Hig Rada Toksikol       Date:  2021-06-28       Impact factor: 2.078

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.